Product Specifications
| Catalog Number | BIC-7535E |
|---|---|
| Target | Noggin |
| Target Symbol | NOG |
| Species | Human |
| Expression System | CHO |
| Expression Region | Gln28-Cys232 |
| Molecular Weight | 23 kDa |
| Purity | ≥95%, by SDS-PAGE (under reducing (R) & Non-reducing conditions, visualized by Coomassie staining). |
| Endotoxin | ≤10 EU/mg by the LAL method. |
| Formulation | Lyophilized |
| Buffer | PBS, 5% Mannitol and 0.01% Tween 80, pH7.4. |
| Reconstitution | It is recommended to redissolve in sterile deionized water. |
| Storage & Stability | 36 months at -20°C to -80°C in lyophilized state; 6 months at -20°C to -80°C under sterile conditions after reconstitution; 7-10 days at 2°C to 8°C under sterile conditions after reconstitution; Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping | The product is shipped with blue ice. |
| Lead Time | Products are in stock, but custom products may require further consultation. |
| Accession | Q13253 |
| Alternative Names | Noggin; NOG |
Bioactivity
Measured by its ability to inhibit 5.0 ng/mL of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrocenic cells. The bioactivity of Recombinant Human Noggin (Cat. No. BIC-7535E) is equivalent to competitor.
Quality Data
Recombinant Human Noggin (Cat. No. BIC-7535E) SDS-PAGE under reducing (R) & Non-reducing conditions. The gel was stained with BIC-7535E SDS-PAGE.
Highly consistent bioactivity between different production batches of Recombinant Human Noggin (Cat. No. BIC-7535E) .

